AVROBIO, which is developing gene therapies to treat cancer and rare diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol AVRO. Morgan Stanley, Cowen & Company and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
